LIZ NAPASINDAYAO: Open Payments
NPI 1407500614 · SAN CARLOS, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,416 in 83 payments from 21 companies in 2025. Trend: 2023 $3,292 · 2024 $3,667 · 2025 $4,416
Food & beverage: $4,317Education: $99
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 28 | $978 |
| Madrigal Pharmaceuticals | 7 | $585 |
| Janssen Biotech, Inc. | 7 | $455 |
| Lilly USA, LLC | 7 | $358 |
| Gilead Sciences, Inc. | 7 | $329 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 6 | $239 |
| Phathom Pharmaceuticals, Inc. | 4 | $195 |
| Genentech USA, Inc. | 1 | $144 |
| MDD US Operations, LLC | 1 | $143 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $129 |
Products named: REZDIFFRA, LINZESS, TREMFYA, CREON, OMVOH, XIFAXAN, VOQUEZNA, Ocrevus.
Industry payments across CA — which companies pay providers there.
